Decrease in Binding for the Neuropeptide VIP in Response to Marked Inflammation of the Mucosa in Ulcerative Colitis

Jönsson, Maria; Norrgård, Örjan; Hansson, Magnus; Forsgren, Sture

doi:10.1196/annals.1381.030

Cited by 11 publications

(5 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our observations that the epithelial VPAC1 receptor immunoreactions were clearly weakest in deranged mucosa correspond to the observations we have previously made concerning VIP binding using in vitro receptor autoradiography [34]. Thus, with minor exceptions, the level of binding in the mucosa found in that study was most marked in the UC specimens that showed the most normal morphology [34].…”

Section: Discussionsupporting

confidence: 88%

See 1 more Smart Citation

Epithelial Expression of Vasoactive Intestinal Peptide in Ulcerative Colitis: Down-Regulation in Markedly Inflamed Colon

2011

View full text Add to dashboard Cite

The findings suggest that there is a local production of VIP in the epithelial cells in normal and slightly/moderately inflamed mucosa but not in severely inflamed mucosa. Furthermore, a marked downregulation in VPAC1 receptor expressions occurs in the epithelium in severe UC. Based on the knowledge that VIP can have trophic, healing and anti-inflammatory effects, it is likely that the decrease in VIP mRNA and VPAC1 receptor reactions seen in severely affected mucosa in UC may be associated with adverse effects on intestinal function.

show abstract

Section: Discussionsupporting

confidence: 88%

“…Thus, with minor exceptions, the level of binding in the mucosa found in that study was most marked in the UC specimens that showed the most normal morphology [34]. It is also a fact that the VIP concentrations and levels of VIP innervation have generally been described to be low in UC [6,35,36].…”

Section: Discussionmentioning

confidence: 92%

Epithelial Expression of Vasoactive Intestinal Peptide in Ulcerative Colitis: Down-Regulation in Markedly Inflamed Colon

2011

View full text Add to dashboard Cite

show abstract

“…We identified 28 genes common to UC and CD, and 10 genes which exhibit inverse regulation in UC and CD. Among those 10 genes, 3 of them FGF2, NTS and VIP, were previously associated with IBD [16][17][18][19][20][21][22].…”

Section: Discussionmentioning

confidence: 99%

Expression of Cytokine-Coding Genes BMP8B, LEFTY1 and INSL5 Could Distinguish between Ulcerative Colitis and Crohn’s Disease

Skok

Hauptman

Jerala

et al. 2021

Genes

View full text Add to dashboard Cite

Ulcerative colitis (UC) and Crohn’s disease (CD) are characterized by an imbalance between pro-inflammatory and anti-inflammatory cytokines, interfering with the resolution of inflammation. Due to the crucial role of cytokines, new insights into their profiles in UC and CD would help to improve our understanding of pathogenesis and enable the development of new treatment modalities. We provide an expression profile of cytokines in UC and CD, using bioinformatics approach, and experimental validation of expression of the selected genes. We retrieved data and analyzed the cytokine gene expression profiles of UC and CD. From ten genes with inverse expression, common to CD and UC, BMP8B, LEFTY1 and INSL5 were selected for gene expression experimental validation. Experimentally, BMP8B and INSL5 were down-regulated in both CD and UC but followed the bioinformatics trend. The expression of genes LEFTY1 and BMP8B was statistically significant when comparing UC and CD in colon and the expression of gene LEFTY1 showed statistical significance when CD in ileum and colon were compared. Using the bioinformatics approach and experimental validation, we found differences in expression profiles between UC and CD for INSL5, LEFTY1 and BMP8B. These three promising candidate genes need to be further explored at different levels, such as DNA methylation and protein expression, to provide more evidence on their potential diagnostic role in CD and UC.

show abstract

“…VIP evokes a wide spectrum of biological activities relevant for the pathogenesis of colitis: It is involved in the regulation of the water and electrolyte secretion as well as in the glucose metabolism, controls the peristaltic reflex, and has stressattenuating and immunosuppressive properties (138). Since the N-terminus of VIP is crucial for the VIP binding and a decreased VIP binding was found in the colon of colitis patients (139), inhibitors of dipeptiyl peptidases might be helpful to prolong its half life and stabilize its protective effects on mucosal function and inflammation. The relevance of such mechanisms in vivo remains to be elucidated.…”

Section: Putative Effects Of Dipeptidyl Peptidase and Alanyl-aminopepmentioning

confidence: 99%

Inflammatory bowel diseases: multiple benefits from therapy with dipeptidyl- and alanyl-aminopeptidase inhibitors

Bank¹,

Bohr²,

Reinhold³

et al. 2008

Front Biosci

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBD) are driven by imbalances in innate and acquired immune response. In IBD two dysregulated T cell subsets are in the focus of interest: activated effector T cells and regulatory T cells. These T cell subsets are characterized by a strong expression of the ectopeptidases dipeptidyl peptidase IV (DPIV /CD26) and aminopeptidase N (APN/CD13), which are thought to a role in the control of immune activation and in regulating cellular communication by hydrolyzing bioactive polypeptides. Since inhibitors of both enzymes were shown to be effective in limiting immune activation processes in vitro as well as in vivo, they emerged as new drug candidates for the treatment of diseases associated with an imbalanced T cell response, such as IBD. In this review we intent to throw light on the putative role of DPIV, APN and related enzymes in the regulation of immune and non-immune processes in inflammatory bowel diseases, on possible benefits from peptidase inhibitor therapy in these diseases as well on the gaps of knowledge in this field.

show abstract

Decrease in Binding for the Neuropeptide VIP in Response to Marked Inflammation of the Mucosa in Ulcerative Colitis

Cited by 11 publications

References 21 publications

Epithelial Expression of Vasoactive Intestinal Peptide in Ulcerative Colitis: Down-Regulation in Markedly Inflamed Colon

Epithelial Expression of Vasoactive Intestinal Peptide in Ulcerative Colitis: Down-Regulation in Markedly Inflamed Colon

Expression of Cytokine-Coding Genes BMP8B, LEFTY1 and INSL5 Could Distinguish between Ulcerative Colitis and Crohn’s Disease

Inflammatory bowel diseases: multiple benefits from therapy with dipeptidyl- and alanyl-aminopeptidase inhibitors

Contact Info

Product

Resources

About